Initiative to develop a citizen’s roadmap for universal health care in India launched
This Commission will base its recommendations on a consultative and participatory effort that brings together key stakeholders across India’s healthcare landscape. December 11, 2020 8:01:12 pm
The commission was initiated in the shadow of the Covid-19 pandemic, which has laid bare the need for a resilient health system.
The long-standing need for universal health coverage (UHC) in India has been brought into sharp focus by the pandemic. A step towards this goal was taken on Friday, with the launch of the Lancet Citizens’ Commission on Reimagining India’s Health System.
Former envoy to US Arun Singh is Expert at Explained tomorrow
Arun Singh, India’s Ambassador in Washington DC through 2015-16 and before that as the Deputy Chief of Mission from October 2008 to April 2013, saw the workings of the Obama Administration closely. December 11, 2020 1:53:10 am
Arun Singh
Joe Biden will enter the White House as President of the United States next month at the end of Donald Trump’s tumultuous four-year administration.
How did the India-US bilateral relationship fare between 2016 and 2020?
The two countries grew closer as strategic partners in the Indo-Pacific and elsewhere, but could not find much common ground on trade, immigration, and climate change policy.
Synopsis
The 10-member panel said SII should submit the outcome of the assessment of AstraZeneca-Oxford University trials done by the UK drug regulator. Pfizer seeks more time for presentation.
Reuters
The panel also said SII has submitted safety data till November 14 and asked for updated safety as well as immunogenicity data from clinical trials in India and the UK.
New Delhi: The Subject Expert Committee (SEC) of the drug regulator did not clear applications of Serum Institute of India (SII) and Bharat Biotech seeking marketing approval for their Covid-19 vaccines at its meeting on Wednesday and asked them to provide updated data, people aware of the deliberations told ET. Pfizer, which had also submitted an application, did not make a presentation to the panel and sought more time to do so.